Evaluation for the Characterization of the Safety Profile of the DiamondTemp™ System for Fast Treatment of Patients With Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-29

Study Completion Date

2019-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to characterize the performance of the DiamondTemp Ablation System for its intended use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

NCT03334630

Paroxysmal Atrial Fibrillation Atrial Fibrillation

COMPLETED NA

ACT DiamondTemp TempeRAture-Controlled and Contact Sensing RF Ablation Clinical Trial for Atrial Fibrillation

NCT02821351

Paroxysmal Atrial Fibrillation

COMPLETED NA

SmartTouch Catheter for Left Anterior Line - SmarT Line Study

NCT02217657

Persistent Atrial Fibrillation

COMPLETED NA

DIAMOND AF Post-Approval Study

NCT05230524

Paroxysmal Atrial Fibrillation

TERMINATED

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

NCT01639495

Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The DiamondTemp Ablation System is indicated for use in patients requiring cardiac electrophysiological mapping (stimulation and recording) and, when used in conjunction with a radiofrequency generator and irrigation pump, for cardiac ablation with monitoring of tissue temperature during ablation.
* In this study, the DiamondTemp Ablation System will be evaluated for the treatment of patients with atrial fibrillation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The DIAMOND FASTR-AF study is a prospective, single-arm trial being performed at multiple centers in Europe.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DiamondTemp Cardiac Ablation System

Cardiac ablation procedure

Group Type EXPERIMENTAL

DiamondTemp Cardiac Ablation System

Intervention Type DEVICE

The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:

* DiamondTemp Ablation Catheter

o Unidirectional and Bidirectional models
* DiamondTemp Catheter-to RFG Cable
* DiamondTemp GenConnect Cable
* DiamondTemp FASTR Generator with Footswitch
* DiamondTemp Irrigation Pump
* DiamondTemp Irrigation Tubing Set

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DiamondTemp Cardiac Ablation System

The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:

* DiamondTemp Ablation Catheter

o Unidirectional and Bidirectional models
* DiamondTemp Catheter-to RFG Cable
* DiamondTemp GenConnect Cable
* DiamondTemp FASTR Generator with Footswitch
* DiamondTemp Irrigation Pump
* DiamondTemp Irrigation Tubing Set

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cardiac ablation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Suitable candidate for intra-cardiac mapping and ablation for arrhythmias
* History of recurrent symptomatic PAF with ≥2 episodes reported within the 365 days
* (12) months prior to enrollment
* At least 1 episode of AF documented by Holter monitor, rhythm strip, trans-telephonic monitor (TTM), or 12-lead ECG prior to enrollment
* Refractory to at least one Class I-IV anti-arrhythmic drug (AAD)
* Eighteen (18) years of age or above

Exclusion Criteria

* Previous left atrial ablation procedure
* Intracardiac thrombus, tumor or other abnormality that precludes catheter introduction and placement
* Known severe cerebrovascular disease or history of cerebrovascular event (\< 1 month)
* Subjects with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR)3 with a GFR ≤ 29. Active gastrointestinal bleeding
* Active infection or fever (\>100.5 F/38 ◦C)
* Sepsis
* Cardiac surgery within the past two months.
* Short life expectancy (\<1 yr.) due to other illnesses, such as cancer or pulmonary, hepatic, or renal disease Significant anemia (hemoglobin \< 8.0 mg/dL)
* Severe uncontrolled systemic hypertension (systolic pressure \> 240 mm Hg within the last 30 days)
* Documented anaphylaxis during previous exposure to angiographic contrast media
* Uncontrolled congestive heart failure (NYHA1 Class III or IV)
* Unstable angina or acute myocardial infarction within the past three months
* Bleeding, clotting disorders, or known thrombosis
* Severe Peripheral vascular disease
* Uncontrolled diabetes
* Heart valve replacement
* Mitral clip (E-valve)
* Women who are of childbearing potential who are currently pregnant or not willing to use contraception for the duration of the study
* Active participation in another investigational protocol currently or the last 30 days
* Unable or unwilling to take anti-coagulants
* Unwilling or unable to comply with any protocol or follow up requirements

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No